Literature DB >> 33459808

Human Family 1-4 cytochrome P450 enzymes involved in the metabolic activation of xenobiotic and physiological chemicals: an update.

Slobodan P Rendic1, F Peter Guengerich2.   

Abstract

This is an overview of the metabolic activation of drugs, natural products, physiological compounds, and general chemicals by the catalytic activity of cytochrome P450 enzymes belonging to Families 1-4. The data were collected from > 5152 references. The total number of data entries of reactions catalyzed by P450s Families 1-4 was 7696 of which 1121 (~ 15%) were defined as bioactivation reactions of different degrees. The data were divided into groups of General Chemicals, Drugs, Natural Products, and Physiological Compounds, presented in tabular form. The metabolism and bioactivation of selected examples of each group are discussed. In most of the cases, the metabolites are directly toxic chemicals reacting with cell macromolecules, but in some cases the metabolites formed are not direct toxicants but participate as substrates in succeeding metabolic reactions (e.g., conjugation reactions), the products of which are final toxicants. We identified a high level of activation for three groups of compounds (General Chemicals, Drugs, and Natural Products) yielding activated metabolites and the generally low participation of Physiological Compounds in bioactivation reactions. In the group of General Chemicals, P450 enzymes 1A1, 1A2, and 1B1 dominate in the formation of activated metabolites. Drugs are mostly activated by the enzyme P450 3A4, and Natural Products by P450s 1A2, 2E1, and 3A4. Physiological Compounds showed no clearly dominant enzyme, but the highest numbers of activations are attributed to P450 1A, 1B1, and 3A enzymes. The results thus show, perhaps not surprisingly, that Physiological Compounds are infrequent substrates in bioactivation reactions catalyzed by P450 enzyme Families 1-4, with the exception of estrogens and arachidonic acid. The results thus provide information on the enzymes that activate specific groups of chemicals to toxic metabolites.

Entities:  

Keywords:  Bioactivation; CYP families 1–4; Cytochrome P450; Natural products; P450; Xenobiotics

Year:  2021        PMID: 33459808      PMCID: PMC7880545          DOI: 10.1007/s00204-020-02971-4

Source DB:  PubMed          Journal:  Arch Toxicol        ISSN: 0340-5761            Impact factor:   5.153


  521 in total

1.  Role of P450 1A1 and P450 1A2 in bioactivation versus detoxication of the renal carcinogen aristolochic acid I: studies in Cyp1a1-/-, Cyp1a2-/-, and Cyp1a1/1a2-/- mice.

Authors:  Volker M Arlt; Kateřina Levová; František Bárta; Zhanquan Shi; James D Evans; Eva Frei; Heinz H Schmeiser; Daniel W Nebert; David H Phillips; Marie Stiborová
Journal:  Chem Res Toxicol       Date:  2011-09-29       Impact factor: 3.739

2.  Evaluation of the interindividual human variation in bioactivation of methyleugenol using physiologically based kinetic modeling and Monte Carlo simulations.

Authors:  Ala A A Al-Subeihi; Wasma Alhusainy; Reiko Kiwamoto; Bert Spenkelink; Peter J van Bladeren; Ivonne M C M Rietjens; Ans Punt
Journal:  Toxicol Appl Pharmacol       Date:  2014-12-27       Impact factor: 4.219

3.  Oxidation of N,N-dimethylformamide and N,N-diethylformamide by human liver microsomes and human recombinant P450s.

Authors:  G Amato; E Grasso; V Longo; P G Gervasi
Journal:  Toxicol Lett       Date:  2001-10-15       Impact factor: 4.372

4.  Microsomal ethanol oxidizing system activity by human hepatic cytochrome P450s.

Authors:  H Asai; S Imaoka; T Kuroki; T Monna; Y Funae
Journal:  J Pharmacol Exp Ther       Date:  1996-05       Impact factor: 4.030

5.  Human cDNA-expressed cytochrome P450 IA2: mutagen activation and substrate specificity.

Authors:  T Aoyama; F J Gonzalez; H V Gelboin
Journal:  Mol Carcinog       Date:  1989       Impact factor: 4.784

6.  Use of genetically engineered Salmonella typhimurium OY1002/1A2 strain coexpressing human cytochrome P450 1A2 and NADPH-cytochrome P450 reductase and bacterial O-acetyltransferase in SOS/umu assay.

Authors:  P Aryal; T Terashita; F P Guengerich; T Shimada; Y Oda
Journal:  Environ Mol Mutagen       Date:  2000       Impact factor: 3.216

7.  Functional analysis of six different polymorphic CYP1B1 enzyme variants found in an Ethiopian population.

Authors:  Eleni Aklillu; Mikael Oscarson; Mats Hidestrand; Brith Leidvik; Charlotta Otter; Magnus Ingelman-Sundberg
Journal:  Mol Pharmacol       Date:  2002-03       Impact factor: 4.436

Review 8.  Aristolochic acid as a probable human cancer hazard in herbal remedies: a review.

Authors:  Volker M Arlt; Marie Stiborova; Heinz H Schmeiser
Journal:  Mutagenesis       Date:  2002-07       Impact factor: 3.000

9.  Mechanism-based inactivation of cytochrome P450 3A4 by 4-ipomeanol.

Authors:  Teresa M Alvarez-Diez; Jiang Zheng
Journal:  Chem Res Toxicol       Date:  2004-02       Impact factor: 3.739

Review 10.  Aristolochic acid mutagenesis: molecular clues to the aetiology of Balkan endemic nephropathy-associated urothelial cancer.

Authors:  Volker M Arlt; Marie Stiborová; Jochen vom Brocke; Maria L Simões; Graham M Lord; Joelle L Nortier; Monica Hollstein; David H Phillips; Heinz H Schmeiser
Journal:  Carcinogenesis       Date:  2007-04-13       Impact factor: 4.944

View more
  11 in total

1.  In-line formation and identification of toxic reductive metabolites of aristolochic acid using electrochemistry mass spectrometry coupling.

Authors:  Ugo Bussy; Renaud Boisseau; Mikaël Croyal; Ranil C T Temgoua; Mohammed Boujtita
Journal:  Anal Bioanal Chem       Date:  2022-01-13       Impact factor: 4.142

Review 2.  Roles of selected non-P450 human oxidoreductase enzymes in protective and toxic effects of chemicals: review and compilation of reactions.

Authors:  Slobodan P Rendić; Rachel D Crouch; F Peter Guengerich
Journal:  Arch Toxicol       Date:  2022-06-01       Impact factor: 6.168

Review 3.  Candidate Proficiency Test Chemicals to Address Industrial Chemical Applicability Domains for in vitro Human Cytochrome P450 Enzyme Induction.

Authors:  Miriam Naomi Jacobs; Barbara Kubickova; Eugene Boshoff
Journal:  Front Toxicol       Date:  2022-06-20

4.  The Role of CYP2B6*6 Gene Polymorphisms in 3,5,6-Trichloro-2-pyridinol Levels as a Biomarker of Chlorpyrifos Toxicity Among Indonesian Farmers.

Authors:  Jen Fuk Liem; Dwi A Suryandari; Safarina G Malik; Muchtaruddin Mansyur; Dewi S Soemarko; Aria Kekalih; Imam Subekti; Franciscus D Suyatna; Bertha Pangaribuan
Journal:  J Prev Med Public Health       Date:  2022-05-16

Review 5.  Molecular Mechanisms of Action of Selected Substances Involved in the Reduction of Benzo[a]pyrene-Induced Oxidative Stress.

Authors:  Bożena Bukowska; Piotr Duchnowicz
Journal:  Molecules       Date:  2022-02-18       Impact factor: 4.411

6.  Phytochemical Composition and Protective Effect of Vernonanthura polyanthes Leaf against In Vivo Doxorubicin-Mediated Toxicity.

Authors:  Jamira Dias Rocha; Marilia Elias Gallon; Abel Vieira de Melo Bisneto; Vanessa Cristiane Santana Amaral; Luciane Madureira de Almeida; Leonardo Luiz Borges; Lee Chen-Chen; Leonardo Gobbo-Neto; Elisa Flávia Luiz Cardoso Bailão
Journal:  Molecules       Date:  2022-04-15       Impact factor: 4.927

Review 7.  Therapeutic benefits of Salvia species: A focus on cancer and viral infection.

Authors:  Chinonso Anthony Ezema; Timothy Prince Chidike Ezeorba; Rita Ngozi Aguchem; Innocent Uzochukwu Okagu
Journal:  Heliyon       Date:  2022-01-13

8.  The Fagerström and AUDIT Tests as Probable Screening Tools in Oral Cancer and Their Correlation with CYP1A1, GSTM1, GSTP1, and GSTT1 Gene Expression.

Authors:  Celso Muller Bandeira; Adriana Ávila Almeida; Mônica Ghislaine Oliveira Alves; Maria Beatriz Nogueira Pascoal; José Francisco Sales Chagas; Morun Bernardino Neto; Patrícia Pimentel de Barros; Fábio Daumas Nunes; Celina Faig Lima Carta; Janete Dias Almeida
Journal:  Int J Environ Res Public Health       Date:  2022-03-27       Impact factor: 3.390

9.  Pyrrolizidine alkaloids cause cell cycle and DNA damage repair defects as analyzed by transcriptomics in cytochrome P450 3A4-overexpressing HepG2 clone 9 cells.

Authors:  Sara Abdelfatah; Janine Naß; Caroline Knorz; Sabine M Klauck; Jan-Heiner Küpper; Thomas Efferth
Journal:  Cell Biol Toxicol       Date:  2021-04-21       Impact factor: 6.691

Review 10.  The "beauty in the beast"-the multiple uses of Priestia megaterium in biotechnology.

Authors:  Rebekka Biedendieck; Tobias Knuuti; Simon J Moore; Dieter Jahn
Journal:  Appl Microbiol Biotechnol       Date:  2021-07-15       Impact factor: 4.813

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.